Why the Vertex Price Target Just Got Tweaked The small lift in Vertex Pharmaceuticals' fair value estimate to US$496.16 per ...

Vertex Pharmaceuticals (VRTX) is back in focus after Wolfe Research upgraded the stock to Outperform, citing increased ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.24% at $463.86. This change lagged the S&P 500's daily ...

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the meantime, other healthcare leaders could perform significantly better this year ...

If you are wondering whether Vertex Pharmaceuticals' current share price reflects its long term potential, a useful starting ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $469.68, marking a -2.99% move from the previous day.

BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $522 from $545 and keeps a Buy rating on the shares after the company reported topline Phase 2 results for suzetrigine in ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $496.45, a high estimate of $564.00, and a low estimate of $414.00. Witnessing a positive shift, the ...

Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the positions showed up on ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed yesterday at ...